Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Drug Research
Return to: PBR Home | Drug Research
Today in Drug Research

Drug Research

Servier buys development and commercialization rights of OSE’s Effi-7 French pharma Servier has acquired the exclusive global rights for development and commercialization of OSE Immunotherapeutics’ Effi-7 in a licence option deal that could worth €272m. News

Latest Drug Research News by Sector

Select a sector from the list or browse by sector below:

Drug Delivery

Kalobios secures green light from FDA to proceed with Chagas disease drug
KaloBios Pharmaceuticals announced positive guidance from a recent meeting with with the US Food and Drug Administration (FDA) to discuss the development plans for benznidazole to treat Chagas disease, a neglected tropical disease.
Drug Research > Drug Delivery > News
RaNA Therapeutics acquires Messenger RNA Platform from Shire
RaNA Therapeutics has acquired the MRT platform, an mRNA therapy platform, developed by subsidiaries of Shire.
Drug Research > Drug Delivery > News

Drug Discovery & Development

Clinical-stage biopharmaceutical firm OncoImmune raises $15m funding
OncoImmune, a privately-held, clinical-stage biopharmaceutical company that is actively engaged in the discovery and development of novel immunotherapies for cancer, inflammation and autoimmune diseases, has secured $15m in Series A round of fundraising led by 3E Bioventures Capital.
Drug Research > Drug Discovery & Development > News
Merck expands oncology portfolio with four Vertex cancer programs
By PBR Staff Writer
Merck has agreed to license four oncology research and development (R&D) programs from Vertex Pharmaceuticals.
Drug Research > Drug Discovery & Development > News